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Introduction: Accurate staging of lymph node involvement is a
critical aspect of the initial management of nonmetastatic non-small
cell lung cancer (NSCLC). We sought to determine whether the
current N descriptors should be maintained or revised for the next
edition of the international lung cancer staging system.
Methods: A retrospective international lung cancer database was
developed and analyzed. Anatomical location of lymph node in-
volvement was defined by the Naruke (for Japanese data) and
American Thoracic Society (for non-Japanese data) nodal maps.
Survival was calculated by the Kaplan-Meier method, and prognos-
tic groups were assessed by Cox regression analysis.
Results: Current N0 to N3 descriptors defined distinct prognostic
groups for both clinical and pathologic staging. Exploratory analyses
indicated that lymph node stations could be grouped together into
six “zones”: peripheral or hilar for N1, and upper or lower medias-
tinal, aortopulmonary, and subcarinal for N2 nodes. Among patients
undergoing resection without induction therapy, there were three
distinct prognostic groups: single-zone N1, multiple-zone N1 or
single N2, and multiple-zone N2 disease. Nevertheless, there were
insufficient data to determine whether the N descriptors should be
subdivided (e.g., N1a, N1b, N2a, N2b).
Conclusions: Current N descriptors should be maintained in the
NSCLC staging system. Prospective studies are needed to validate
amalgamating lymph node stations into zones and subdividing N
descriptors.
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Accurate staging of lymph node involvement is a criticalaspect of the initial management of patients with non-
metastatic non-small cell lung cancer (NSCLC) that influ-
ences decisions about the appropriateness and timing of
surgery, radiation, and systemic therapy. Since the lung
cancer staging system was first developed in 1973,1 lymph
node involvement has been categorized as N0 (no nodes
involved), N1 (peribronchial, interlobar, or perihilar lymph
nodes involved), N2 (ipsilateral mediastinal nodes involved),
or N3 (contralateral mediastinal or supraclavicular nodes
involved). The classification of these N descriptors into the
overall tumor stages of I through III has been used to predict
outcomes and to assist in treatment selection. During the past
20 years, numerous studies have evaluated the validity of the
N descriptors and have suggested that these could be refined
to provide more accurate prognostic stratification by subdi-
viding them either according to specific anatomical locations
(e.g., N1 peribronchial versus N1 perihilar) or the number of
involved lymph nodes (e.g., single versus multiple N2
nodes).2–27 This study was undertaken as part of the effort by
the staging committee of the International Association for the
Study of Lung Cancer (IASLC) to determine whether the
current international lung cancer staging system required
revision in preparation for the seventh edition of the Union
Internationale Contre le Cancer (UICC) and American Joint
Commission on Cancer (AJCC) cancer staging manuals. We
sought to define whether the current N descriptors for
NSCLC should be maintained or revised.
METHODS
Data Acquisition and Analysis
The process for the development of the IASLC lung
database has been described previously.28 Briefly, the data-
base was developed through an international consortium of
institutions and clinical trials groups that submitted staging
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and outcomes data on a total of 100,869 lung cancer cases
managed within the time frame of 1990 to 2000. Data were
collected retrospectively from 47 preexisting databases,
which varied widely in terms of the levels of detail provided.
Data management and statistical analyses were provided by
coinvestigators at Cancer Research and Biostatistics in Seattle,
Washington. Of the 81,015 lung cancer patients and the
67,725 NSCLC patients who met the initial screening re-
quirements of a complete set of tumor, node, metastasis
(TNM) by either clinical or pathological staging, known
histological type, and survival follow-up, 38,265 patients
with no clinical evidence of metastatic disease (cM0) had
information on clinical N staging (cN), and 28,371 surgically
managed patients provided information on pathologic N stag-
ing (pN). Clinical staging included all tests and imaging
studies done for initial extent-of-disease evaluation and in-
formation obtained from mediastinoscopy, but not from tho-
racotomy. Positron emission tomography (PET) was not in
widespread use internationally during the time frame of this
study, so PET data for clinical staging were not available.
Pathological staging included all of the information available
from clinical staging plus the pathological information from
specimens obtained at thoracotomy. Twelve of the 47 data-
bases submitted to the project included data on sampling
results (positive, negative, not done) for individual nodal
stations. Further analyses of overall survival in relation to
subsets of pN1 and pN2 stages were performed for 2876
patients who underwent R0 (microscopically complete) re-
section without induction therapy and who successfully met
logic checks of pN stage for data accuracy (pN stage in
relation to highest positive nodal station recorded). Of these,
1721 cases (60%) were submitted from Japan, 701 cases
(24%) came from Europe, 380 (13.2%) were from North
America, and 74 (2.6%) were from Australia or Taiwan.
The minimum lymph node stations for which documenta-
tion was available from all contributing groups included
nodal level 2 and levels 4 through 9. All but one group
provided documentation for levels 11 and 12, and most
groups provided documentation for supraclavicular lymph
nodes and nodes at levels 1, 13, and 14. Documentation of
level 3 nodes was available from half of the contributing
groups.
FIGURE 1. Naruke lymph node map. From: The Japan Lung Cancer Society. Classification of Lung Cancer, 1st English Ed.
Tokyo: Kanehara & Co., 2000.29 Used with permission.
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Surgical cases from Japan were staged according to the
Naruke lymph node map, adopted by the Japan Lung Cancer
Society as the official staging map (Figure 1).29 Those from
all other countries were staged according to the Mountain-
Dresler modification of the American Thoracic Society (MD-
ATS) map (Figure 2).30–32 From the perspective of grouping
lymph node stations into N1 versus N2 categories, the main
discrepancy between these two lymph node maps is that the
Naruke map considers lymph nodes in the subcarinal space
along the inferior border of the mainstem bronchus to be
station 10 (hence, N1), whereas these are labeled as level 7
(and, therefore, N2) in the MD-ATS map. Within the context
of a retrospective analysis, there was no way to reconcile this
inherent difference in the designation of subcarinal lymph
nodes. A lesser discrepancy between these two maps occurs
in the labeling of lymph nodes from the right paratracheal
region. Lymph nodes located between the right main pulmo-
nary artery and the origin of the innominate artery are labeled
as right level 4 (R4) in the MD-ATS map, whereas in the
Naruke map the upper half of this region is considered level
2 (R2), and only the nodes located between the right main
pulmonary artery and the superior border of the azygos vein
are considered 4R. Nevertheless, all of these lymph nodes
would be considered N2 according to either mapping system.
This difference in nomenclature introduces an irreconcilable
but likely small discrepancy in data analysis (Table 1).
Statistical Methodology
Survival was measured from the date of entry (date of
diagnosis for registries, date of registration for protocols) for
clinically staged data and from the date of surgery for
pathologically staged data; it was calculated by the Kaplan-
Meier method. Prognostic groups were assessed by Cox
regression analysis, using the SAS System for Windows
version 9.0 PHREG procedure.
FIGURE 2. Mountain-Dresler lymph node map. The lymph node “zones” used for analyses in this study are shown superim-
posed on the MD-ATS map. From: Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging.
Chest 1997;111:1718–1723.30 Used with permission.
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RESULTS
Overall Survival According to Clinical N Staging
The overall survival by cN staging for all 38,265 cM0
(any T stage) patients is shown in Figure 3. These survival
curves show clear differences in outcome for each of the cN
categories. Additional analyses indicate that these differences
in outcome occurred predominantly among the clinically
staged patients who underwent surgical treatment. For the
clinically staged cM0 patients who were managed nonsurgi-
cally (n  15,451), the median and 5-year survival rates
ranged, respectively, from 13 months and 9% for N0 to 9
months and 5% for N3 disease (data not shown). Whether the
absence of survival differences for patients managed nonsur-
gically reflects the lack of efficacy of available treatment, the
influence of medical comorbidities, or both, cannot be deter-
mined from this database.
Overall Survival According to Pathological N
Staging
The overall survival by pN staging for the 28,371 cM0
(any T stage) patients who were managed surgically (and who
had no evidence of intrathoracic M1 disease at thoracotomy) is
shown in Figure 4. These survival curves again show significant
differences in outcome for each of the pN categories. Figure 4
also shows the survival rates for surgically managed patients for
whom cN staging information was available (n 22,814), again
indicating distinct differences in outcome for each N category.
Comparison of the survival rates by cN and pN indicates that the
additional information provided from pathological staging de-
fines a group of N0 stage tumors with better survival and a group
of N3 stage tumors with worse survival than expected from
clinical staging alone.
Relationships between the Site of the Primary
Tumor and the Presence of Lymph Node
Metastases
Information on the site of the primary tumor in rela-
tionship to the presence of lymph node metastases (pN) was
available from 2538 N1 and N2 cases. There were slightly
more upper-lobe (n  1385; 56%) than lower-lobe tumors.
The upper-lobe tumors were associated with the highest
frequency of N1 (n  551; 53%) and N2 (59%) nodal
metastases. The right middle lobe was the least common
primary tumor site. Among the primary tumors that had only
a single involved N2 lymph node station, the most common
site of lymph node metastases was level 4R for right upper-
lobe tumors (191/280; 68%), levels 5/6 for left upper-lobe
tumors (195/251; 78%), and level 7 for middle- and lower-
lobe tumors (228/353; 65%).
TABLE 1. Comparison of Nomenclature of Lymph Node
Stations in the Japanese (Naruke) vs. Mountain-Dresler
Modification of American Thoracic Society (ATS) Maps
Japanese Mountain-Dresler (ATS)
Level 1 Levels 1 and 2
Levels 2, 3, 4R, 4L Levels 4R and 4L
Levels 7 and 10 (subcarinal) Level 7
FIGURE 3. Survival by cN for all cM0 patients.
FIGURE 4. Survival by cN for sur-
gically managed patients.
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Survival in Relationship to the Extent of N1
and N2 Disease in Cases with pN Staging
Exploratory analyses were performed to determine
whether, in patients with pN staging, survival was influenced
by the anatomical location of involved lymph nodes, by the
presence of “skip metastases” (N2 disease in the absence of
N1), or by the number of involved lymph node stations. The
522 N1 cases with involvement of peribronchial levels 12 to
14 were evaluated to determine whether survival was influ-
enced by involvement of the peribronchial (levels 12–14)
TABLE 2. Comparison of Survival According to Involvement of Specific Peripheral
Lymph Node Stations (2a), Single Lymph Node Zones (2b), and Presence of Skip
Metastases (2c)
2a: Specific Peripheral Lymph Node Stations
Lymph Node Station n Median Survival (mo) p
12 (or higher) vs. 11, 10
12 only 361 51
12 11 10 84 48 12 11 10 vs 12 only 0.5876
12 11 10 46 36 12 11 10 vs 12 only 0.0592
12 11 10 31 28 12 11 10 vs 12 only 0.0974
12 11 10 vs 12 11 10 0.2340
2b: Single Lymph Node Zones
Lymph Node Station n Median Survival (mo) p
Single zone: right
P only 324 56
H only 45 63 H only vs P only 0.8548
LM only 8 34 LM only vs P only 0.2303
S only 151 37 S only vs P only 0.0535
S only vs LM only 0.7775
U only 151 37 U only vs P only 0.0069
U only vs LM only 0.7131
U only vs S only 0.8869
Single zone: left
P only 262 52 P only
H only 51 40 H only vs P only 0.8156
LM only 9 39 LM only vs P only 0.1422
S only 17 43 S only vs P only 0.2039
S only vs LM only 0.6688
AP only 64 44 AP only vs P only 0.3923
AP only vs LM only 0.3189
AP only vs S only 0.5149
2c: Presence of Skip Metastases
Lymph Node Station n Median Survival (mo) p
RUL upper zone, figure
U P H 142 37
U P H 97 44 U P H vs U P H 0.5373
U P H 23 40 U P H vs U P H 0.8266
U P H 55 28 U P H vs U P H 0.1878
LUL AP zone, figure
AP P H 86 44
AP P H 45 32 AP P H vs AP P H 0.3878
AP P H 13 27 AP P H vs AP P H 0.6433
AP P H 38 24 AP P H vs AP P H 0.0427
U, upper mediastinal (levels 1–4); AP, aortopulmonary (levels 5 and 6); S, subcarinal (level 7); LM, lower mediastinal
(levels 8 and 9); H, hilar (levels 10 and 11); P, peripheral (levels 12–14); RUL, right upper lobe; LUL, left upper lobe.
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versus the interlobar (level 11) or hilar (level 10) lymph
nodes, or by combinations of these. No significant differences
in survival could be identified (Table 2a), apart from the
general finding that survivorship decreased as the number of
positive stations increased.
To reconcile the Naruke and MD-ATS lymph node
maps and to permit analyses of cases with N1 and, especially,
N2 disease to include larger numbers of patients, lymph node
stations were grouped together into anatomical “zones.”
Lymph nodes at levels 1 through 4 were grouped together
into the upper zone, levels 5 and 6 into the aortopulmonary
(AP) zone, level 7 into the subcarinal zone, levels 8 and 9 into
the lower zone, levels 10 and 11 into the hilar zone, and levels
12 to 14 into the peripheral zone (Figure 2). The appropri-
ateness of grouping lymph node stations into zones was
suggested by exploratory analyses that failed to identify
significant differences in survival in relation to disease in all
of the various N1 and N2 lymph node stations in the data
submitted from Japan, from non-Japanese groups, or both
(data not shown). As shown in Table 2b, significant differ-
ences in survival for patients with lymph node metastases
confined to a single zone were seen only for cases of right-
sided tumors with upper- or subcarinal zone disease com-
pared with peripheral zone metastases. No differences in
survival were identified among patients who had single-zone
N2 disease.
Potential differences in survival were analyzed for
cases with skip metastases, focusing on upper-lobe tumors,
which are thought to be most frequently associated with
these. AP zone disease in the absence of N1 metastases was
associated with a better survival rate in patients with left
upper-lobe tumors, but similar differences in survival were
not identified for right upper-lobe tumors with right paratra-
cheal nodal metastases (Table 2c).
The potential impact of the number of involved lymph
node zones on survival was then examined. As can be seen in
Figure 5, three groups were found to have significantly different
survival rates: patients who had N1 single-zone disease, those
who had either multiple N1 or single N2 zone metastases, and
those who had multiple N2 lymph node zones involved.
These prognostically distinct groups suggested that it might
be appropriate to subdivide the current N staging descriptors
into N1a (single N1 zone), N1b (multiple N1 zones), N2a
(single N2 zone), and N2b (multiple N2 zones). To determine
whether such a revision to the staging system should be
considered, these additional N categories were analyzed in
conjunction with each T stage category (e.g., T1N1a, T1N1b,
T1N2a, T1N2b, etc.) rather than across all T stages, as was
done for all of the preceding analyses. Nevertheless, the
number of patients available in each of these subsets was too
small to yield statistically valid analyses. Therefore, on the
basis of the available data, we cannot recommend altering the
current N stage descriptors.
DISCUSSION
Accurate staging of lymph node involvement has long
been recognized as a key aspect of the initial management of
NSCLC that helps in selecting treatment and predicting
outcome. In patients undergoing surgery for possible resec-
tion of NSCLC, careful assessment of potential nodal disease
has gradually become an accepted part of the operation since
Cahan first described radical mediastinal lymph node dissec-
tion in the early 1950s.1,33 For similar reasons, mediastinos-
copy and imaging studies such as CT (computed tomography)
and PET scanning have become standard components of the
initial clinical staging of NSCLC.31 The development of the
Naruke and, subsequently, of the ATS lymph node maps,
provided standard nomenclature used by all clinicians and
pathologists involved in the care of NSCLC patients to assist
in uniform N staging. Traditionally, these maps labeled N2 or
N3 nodes with single-digit numbers (nodal stations 1–9) and
N1 nodes with double-digit numbers (nodal stations 10–14).
From the inception of the AJCC and UICC lung cancer
staging systems in 1973, the N0, N1, N2, and N3 descriptors
were used to help establish stage classifications for both
clinical and pathological staging. The fifth edition of the lung
cancer staging system, based on a database developed by Dr.
Clifton Mountain of 5319 cases (4351 patients treated at the
MD Anderson Cancer Center, and 968 from other North
American centers), led to a revision of the stage classifica-
tions but maintained the existing distinctions among the N
descriptors.34 In the absence of compelling alternative data,
no changes were made to the sixth edition of the AJCC and
UICC staging system. The current IASLC database includes
a much larger number of cases from databases around the
world on which to test the validity of the current staging
system. Our data show that the N0, N1, N2, and N3 descrip-
tors, whether derived from clinical or pathological staging,
clearly identify prognostically distinct groups of patients, and
it is therefore appropriate to maintain these descriptors in the
upcoming seventh version of the lung cancer staging system.
Notably, the IASLC database is the first international data-
base that has shown these descriptors to have internal and
external validity.
FIGURE 5. Survival by N status and number of involved N
zones.
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During the past 25 years, numerous studies have exam-
ined the patterns of lymphatic drainage of the lung and have
analyzed the influence of N1 and N2 lymph node involve-
ment on overall survival. These series are retrospective, are
based on pathological staging, and include relatively small
numbers of patients.2–27 Among patients undergoing surgery
for NSCLC, our data corroborate the findings of other studies,
including a higher frequency of upper-lobe tumors and a
predominance of lymphatic drainage to the superior medias-
tinum for right upper-lobe tumors, to the AP region for left
upper-lobe tumors, and to the subcarinal area for middle- and
lower-lobe tumors.18,20,24–26,35 Previous studies suggest that
survival is significantly worse in patients who have hilar or
interlobar rather than only peribronchial lymph node involve-
ment or that multiple levels of N1 nodal disease are associ-
ated with a worse outcome than single-level disease (Table
3). We were unable to identify differences in outcome for
patients with peripheral versus hilar N1 disease, but we found
that survival was significantly worse in cases of multiple
versus single levels of N1 nodal metastases.
Differences in nomenclature between the Naruke and
the MD-ATS lymph node maps pose challenges for the
TABLE 3. Results of Series Reporting the Outcome of Patients Who Underwent
Resection for Non-small Cell Lung Cancer with N1 Disease
5-Year Survival (%)
Authors (Year) No. of Patients Overall () Hilar () Interlobar () Peripheral
Ferguson et al.2 (1986) 34 30.2 NS NS NS
Maggi et al.3 (1990) 157 46.1 NS NS NS
Martini et al.4 (1992) 214 39 NS NS NS
Yano et al.5 (1994) 78 49.2 39.7* 64.5
van Velzen et al.6 (1996) 57 45.7 23.3* 55.6
van Velzen et al.7 (1997) 369 37.8 30.3* 57.3
van Velzen et al.8 (1999) 111 27.2 NS NS NS
Sawyer et al.9 (1999) 107 32 NS NS NS
Riquet et al.10 (1999) 256 47.5 38.5* 52.6
Yoshino et al.11 (1999) 43 50.2 47.4* 55
Asamura et al.12 (2000) 180 67 54 70†
Marra et al.13 (2003) 535 40 30 39 41
NS, not shown.
*Hilar and interlobar were analyzed as a single group.
†Interlobar and peripheral were analyzed as a single group.
TABLE 4. Results of a Series Reporting the Outcome of Patients Who Underwent
Resection for Non-small Cell Lung Cancer with N2 Disease
5-Year Survival (%)
Author (Year) No. of Patients Overall Single Level Multi Level p
Naruke et al.14 (1978) 77 18.8 NR NR NR
Martini et al.15 (1983) 151 29 25 33 NR
Miller et al.16 (1994) 147 23.7 30 0–30, depending on
number of stations
0.02
Goldstraw et al.17 (1994) 149 20.1 30 (3 yr) 25 (3 yr) 0.05
Riquet et al. (1995)18 237 18.8 26.3 8.3 0.0003
Vansteenkiste et al.35 (1997) 140 20.8 19.5 22 0.20
Okada et al.19 (1999) 141 26 39 11 0.0001
Asamura et al.20 (1999) 166 35 48 18 0.006
Sagawa et al.21 (1999) 178 28 41 13 0.001
Andre et al.22 (2000) 702 18 25 7 0.0001
Naruke et al.23 (2001) 736 19.9 NR NR NR
Ichinose et al.24 (2001) 402 31 43 17 0.0001
Ueda et al.25 (2003) 96 30 35 19 0.019
Inoue et al.26 (2004) 154 28.1 42.7 15.5 0.0001
Keller et al.27 (2004) 172 NR 32 NR NR
NR, not reported.
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analysis of an international database. Reconciliation of these
maps is the subject of a separate study (which is being
undertaken by the IASLC staging committee) and is, there-
fore, not discussed in detail here. Nevertheless, our explor-
atory analyses suggested that for the purposes of analyzing N
stages, it was statistically appropriate to consolidate several
lymph node stations from both mapping systems together into
zones. This approach allowed us to address the findings of
previous studies that skip metastases and single-level N2
disease are both associated with better survival rates than
involvement of multiple N2 lymph node stations (Table 4). In
contrast with previous studies,36–43 we were able to identify
a better survival rate only for patients with left upper-lobe
tumors with AP zone N2 disease—not for patients with right
upper-lobe tumors with metastases confined to the superior
mediastinum. These results should be interpreted with cau-
tion because the numbers of patients available for these
subset analyses are relatively small.
The most salient finding with respect to pN staging in
our database is that patients fall into three prognostically
distinct categories, depending on the extent of nodal metas-
tases: single-zone N1, multiple-zone N1 or single-zone N2,
and multiple-zone N2. In conjunction with our other analyses,
these results suggest that the overall disease burden, rather
than just the anatomical location of lymph node involvement,
may have the most important influence on outcome. These
three categories have not been clearly identified in previous
studies (Table 3 and 4), which have focused predominantly
on comparing survival relative to varying levels of either N1
or N2 disease. Validating this finding in a way that would be
statistically sound enough to warrant a change in the N descrip-
tors for the staging system would clearly require a prospective
study of even larger numbers of patients with meticulous pN
staging. Nevertheless, our results provide the impetus for such a
study and the rationale for stratifying patients according these
three prognostic groups in clinical trials.
In summary, analyses of clinical and pathological N
staging in the IASLC database support the continued use of
the current N descriptors in the lung cancer database. Addi-
tional analyses suggest that consolidation of multiple lymph
node stations into zones and stratification of patients into
three groups according to the extent of nodal disease may be
appropriate and warrant inclusion in future studies.
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